Gujarat Themis Biosyn promoter Sachin Patel to acquire up to 2.38% stake for Rs 100 cr

What Gujarat Themis Biosyn announced

On 24 June 2026, Gujarat Themis Biosyn Ltd (BSE code 506879) filed a disclosure under SEBI Regulation 10(5) indicating that promoter Sachin D. Patel intends to acquire equity shares from Themis Medicare Limited. The move is an inter‑se transfer within the promoter group and is exempt from the mandatory open‑offer requirement under Regulation 10(1)(a)(ii).

The acquirer proposes to purchase up to 2,600,000 shares, representing up to 2.38% of the company’s total share capital, at a price of Rs 400.45 per share. At the stated price, the total consideration could reach approximately Rs 100 crore. The transaction is scheduled to be completed between 30 June 2026 and 3 July 2026.

Details of the proposed acquisition

• Acquirer: Sachin D. Patel, promoter of Gujarat Themis Biosyn Ltd.
• Seller: Themis Medicare Limited, a promoter‑group entity.
• Number of shares: Up to 26 lakh equity shares.
• Percentage of share capital: Up to 2.38%.
• Price per share: Rs 400.45.
• Total transaction value: Up to Rs 100 crore (rounded).
• Proposed acquisition window: 30 June 2026 – 3 July 2026.
• Regulatory exemption: Covered under SEBI (SAST) Regulation 10(1)(a)(ii), meaning no open‑offer to other shareholders is required.
• Market price reference: The volume‑weighted average market price (VWAP) for the preceding 60‑day period was Rs 369.15, well below the proposed price, satisfying the 25% premium ceiling.

Rationale for the inter‑se transfer

The filing states that the transfer is an inter‑se transaction among promoters and promoter group members. No commercial rationale beyond the internal re‑allocation of shareholding is provided, which is typical for such intra‑group adjustments. The acquirer has affirmed compliance with all disclosure obligations under the Takeover Regulations for the past three years.

Key facts at a glance

Why this matters for investors

The transaction does not trigger a mandatory open offer, so existing shareholders will not receive any cash consideration from the acquirer. However, the acquisition modestly increases the promoter’s stake, potentially signalling confidence in the company’s prospects or a desire to consolidate control. Because the purchase price (Rs 400.45) exceeds the recent 60‑day VWAP (Rs 369.15) but stays within the 25% premium ceiling, the deal complies with SEBI’s pricing safeguards.

For investors, the key implications are:

• Shareholding dilution: The promoter’s shareholding will rise from a negligible 0.00% to up to 2.38%, marginally altering the promoter‑group influence.
• Capital structure: No new shares are being issued; the transaction is a transfer of existing shares, so the company’s capital base remains unchanged.
• Regulatory compliance: The filing confirms that all statutory disclosures under the Takeover Regulations have been satisfied, reducing regulatory risk.
• Liquidity: Since the shares are transferred between related parties, market liquidity is unlikely to be affected.

Conclusion

Gujarat Themis Biosyn Ltd has disclosed that promoter Sachin D. Patel plans to acquire up to 2.38% of the company’s equity from Themis Medicare Limited for roughly Rs 100 crore, under a SEBI‑approved exemption. The transaction is slated for the last week of June 2026 and does not require an open offer. While the move modestly boosts promoter ownership, the company’s capital structure and market liquidity remain largely unchanged. The filing satisfies all required disclosures, and no further regulatory approvals are pending for the acquisition itself.